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Abstract
The authors present a case of a 16-year-old boy, who was referred
to the hospital due to thrombocytopenia, anemia, proteinuria and
hyperbilirubinemia. Based on the clinical picture and the laboratory
data, thrombotic thrombocytopenic purpura (TTP) was diagnosed.
The adequate therapy was immediately started. TTP is quite a rare
entity. The etiology and the pathogenesis are not well defined. The
authors summarize the different pathomechanisms, which may
play a role in the development of TTP. Similarity to the hemolytic
uremic syndrome (HUS), therapeutic possibilities, prognosis and
the outcome are also discussed. The importance of the early diag-
nosis of TTP in childhood, and life-saving effect of the adequate
treatment are emphasized. Int Pediatr. 2001;16(3):144-149.
Key words: thrombotic thrombocytopenic purpura (TTP), plasma-
pheresis, plasma exchange (PEX)
Introduction
Thrombotic thrombocytopenic purpura (TTP) is a
severe multisystemic disorder characterized by the same
tetrad of clinical findings as hemolytic uremic syndrome
(HUS) (thrombocytopenia, microangiopathic hemolytic
anemia, fluctuating neurological symptoms and impaired
renal function) with the addition of fever.1 Although it is
a disorder of unknown cause, a variety of clinical events
have been identified as possible precipitating factors. In-
fections are the most common precipitation factors, fol-
lowed by pregnancy.2,3 Without treatment, TTP has a
mortality rate in excess of 90% due to multi-organ fail-
ure.4 The authors recognized the clinical signs and the
laboratory data on a 16-year-old patient, and after setting
the diagnosis of thrombotic thrombocytopenic purpura,
adequate therapy was started immediately on the basis of
the current literature. For five months this patient has
received combined therapy. He is now symptom- and com-
plaint-free.
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Case Report
A 16-year-old boy is presented. He is the first child of
his family, after a normal delivery. At the age of 8-months,
he had salmonellosis, and later varicella and mumps. There
was no family history of an inherited disease or bleeding
disorder. Both his parents and his younger brother were
healthy. At 16 years of age, the previously healthy boy
had diarrhea. One day later he had fever and vomited.
These symptoms had disappeared in three days. Two
days later, his family doctor referred him to the hospital
because of proteinuria. In the hospital, anemia, thromb-
ocytopenia, indirect hyperbilirubinemia, severe pro-
teinuria were recognized, and an unclear structure of the
kidneys was seen by an abdominal ultrasound.
During the first physical examination, he appeared
pale, scleral and skin jaundice.  Petechia, and some ec-
chymosis, and submandibular lymphadenomegaly were
detected. His liver was 2 cm under the costal arch.
On his first admission at another institution, he had
profound thrombocytopenia (18.000 G/l), anemia (Hb 9.2
g/dl) with numerous schistocytes (Fig 1). The patient also
had an elevated LDH activity (2116 U/l), indirect hyper-
bilirubinemia (65 µmol/l), decreased level of serum fibrino-
gen (125 mg/dl), hypocalcemia (1.9 mmol/l), and pro-
teinuria. The boy’s urine sediment contained 4-5 red blood
cells and 1-1 leukocytes could be detected.
Microangiopathic hemolytic anemia was diagnosed
based on the clinical findings and laboratory results. The
treatment was symptomatic with forced fluid therapy (in
a dose of 3000 ml/m2), which included infusions of fresh
frozen plasma (FFP).
On the second day of his admission, his hemoglobin
level decreased, the platelet count was stable but low.
Therefore a treatment with regular plasma exchange
(PEX) by plasmapheresis was initiated.
Due to the daily PEX, with replacement of
cryosupernatant, a quick improvement was observed. His
LDH level became normal, serum bilirubin-level de-
creased, hemolysis alleviated, and platelet count increased.
Reticulocytosis was seen as a compensation of the bone
marrow (Fig 2).
After the seventh PEX, severe spastic abdominal pain
occurred; only opioid analgetics were effective. As a cause
of this acute symptom, in addition to the manifestation of
his primary disease, bowel ischemia, hypocalcemia, inspis-
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sated bile syndrome and gallbladder dysfunction had arise,
but none of them could have been proved.
PEX was given to our patient 12 times. All together,
33 liters of plasma were removed, and just as many
cryosupernatants were transfused. One week later, the
platelet count has decreased again without any sign for
hemolysis; therefore oral corticosteroid was given. Dur-
ing the third week, his nursing therapy was completed
with azathioprine and 4 times a day transfusion with
cryosupernatant (Fig 3).
The result of this combined therapy, the blood work
and the laboratory results of our patient became normal,
but still, no clinical finding was recognized. He was treated
with methylprednisolone for 11 weeks and with azathio-
prine for 19 weeks. Remarkably, at six months after set-
ting the diagnosis, he had acute purulent appendicitis, and
three months later, he was admitted to the hospital be-
cause of mastoiditis associated with meningitis. During
this period, the laboratory results were those for acute
bacterial infection. At his last ambulatory control, he was
symptom- and complaint-free; his blood work and labo-
ratory results were normal, with no sign of hemolysis or
relapse of the primary disease.
Discussion
In 1925 Moschcowitz observed widespread hyaline
thrombi in capillaries and arterioles now established as
the pathologic hallmark of TTP. Moschcowitz regarded
these lesions as the result of circulating toxin affecting
platelets and red cells.1
The etiology is unknown, but a variety of clinical
events have been identified as possible precipitating fac-
tors (serotoxin-producing enteropathogenic Escherichia
coli and Shigella dysenteriae infections,2 pregnancy or oral-
contraceptive related,3 malignancy, chemotherapy, mar-
row transplantation, drug-dependent antibodies and con-
nective tissue disease).
The pathogenesis of TTP is heterogeneous. Several
markers and hypothesis have been described in the litera-
ture. Histological findings point to the pathological in-
teraction between vascular endothelium and platelets,
which leads to enhance platelet aggregation and endot-
helial damage. Autopsy findings in TTP reveal multiple
small hyalin-like thrombi occluding capillaries and arte-
rioles in a variety of organs (most frequently the kidneys,
brain, pancreas, heart, spleen and adrenal glands).
Immunohistochemical stains have shown that the
thrombi contain platelets and fibrin and frequently im-
munoglobulin and complement. Cytotoxic effects on en-
dothelial cells have been induced by sera from patients
with TTP.4 Abnormalities of prostacyclin (PGI2), the
platelet-inhibiting eicosanoid synthesized by endothelial
cells, have also been described in TTP. Plasma from some
patients, in contrast to normal plasma, was unable to
stimulate PGI2 synthesis in endothelial cells. ß-
thromboglobulin, a platelet α-granule protein secreted
upon platelet activation, can inhibit endothelial PGI2 syn-
thesis and is a candidate for this activity in patients with
TTP. Others have suggested that a PGI2 deficiency may
be caused by deficiency of a PGI2-stabilizing protein, with
excessive PGI2 degradation.
5 Detection of abnormally large
multimers of the von Willebrand factor in the plasma of
patients with TTP links endothelial cell damage with a
mechanism of platelet aggregation.6 These multimers are
very effective in binding to glycoproteins (Ib and II/IIIa)
on the endothelial cell surface and inducing platelet ag-
gregation. An intracellular cysteine protease, calpain, has
been found in the plasma of many patients with acute
TTP. High molecular weight kininogen is one of the pri-
mary plasma inhibitors of calpain. Kelton et al observed
that the high molecular weight kininogen in plasma
samples from patients with acute TTP was proteolysed.7,8
Fig 1. - Blood smear of our patient, showing red cell fragmenta-
tion (schistocytosis) and marked deficiency of platelet.
Fig 2. - Blood smear of our patient, showing reticulocytosis, re-
flecting the bone marrow response to hemolysis.
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Fibrinolytic activity is depressed at the site of
microthrombi formation. Decreased level of protein C also
has been reported in TTP plasma. Impaired fibrinolysis
may contribute to the stability of the platelet plug and
enhance tissue injury.9
The classic pentad of clinical findings is (1) fever, (2)
thrombocytopenia, (3) microangiopathic hemolytic ane-
mia, (4) neurologic abnormalities, and (5) renal involve-
ment (Table 1). This disease is similar to HUS except
that it occurs most often in young adults, involves more
organ systems, neurologic symptoms are prominent, renal
dysfunction is less severe, and the mortality rate is higher
(Table 2). A variety of manifestations due to damage of
multiple organs are present. Damage to the central ner-
vous system is most common. Headaches, confusion, sei-
zures and coma reflect cerebral lesions. Symptoms may be
reversible, if treated early. Jaundice reflects both hemoly-
sis and liver damage. The widespread thrombotic process
results in visual defects, heart failure, abdominal pain, and
damage to the pancreas and adrenal glands.
Four different types of TTP have been recognized: (1)
single-episode TTP (most common); (2) relapsing TTP,
which characterized by episodes that recur after healthy
periods of months or years; (3) chronic TTP, which is
characterized by very frequent recurrent episodes; (4)
childhood/familial TTP, which is very rare.
Laboratory Findings
TTP is usually apparent from the initial blood count
and examination of blood film. The hemoglobin is usu-
ally less than 10.5 g/dl (average 8 to 9 g/dl). MCV may be
Fig 3. -  Time course of platelet count and LDH values during the hospital courses of our patient with different treatment modalities.
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normal; decreased, if there is marked erythrocyte fragmen-
tation; or increased, depending on the degree of reticulo-
cytosis. MCH and MCHC are normal. Reticulocytes are
increased, and nucleated erythrocytes are found in the
peripheral blood, reflecting the bone marrow response to
hemolysis. The most striking blood finding is the abun-
dance of schistocytes (Fig 4).
Thrombocytopenia is typically severe (8 to 44 /µl) due
to consumption of platelets in the formation of
microthrombi. Platelet survival is very short, and platelet
sequestration studies demonstrate hepatosplenic uptake.
Megakaryocytes are abundant in the bone marrow. The
bleeding time may be prolonged if the platelet count is
less than 100 G/l. Leukocytosis with counts more than 20
G/l occur in 50% of patients and usually accompanied by
a shift to the left. Hemoglobinemia, hemoglobinuria, de-
creased haptoglobin levels and increased serum bilirubin
are direct evidence of intravascular hemolysis. Coagula-
tion tests are usually normal or only mildly disturbed in
TTP, which helps to differentiate TTP from disseminated
intravascular coagulation.
Treatment
Due to the rarity of the condition, several different
treatment modalities have been used. Among them,
plasma exchange recently became the standard therapeu-
tic management for this disease.10 Plasma exchange regi-
ments for TTP should begin with single plasma volume
exchange (40 ml/kg body mass) on a daily basis. Daily
treatments should continue until the resolution of the
thrombocytopenia, neurological abnormalities, the stabi-
lization of the hemoglobin, and the normalization of LDH
level. The standard replacement fluid is FFP, however sev-
eral recent reports described successful use of
cryosupernatant (which is the residual plasma fraction after
the separation of cryoprecipitate and is mostly depleted
of vWF, fibrinogen, fibronectin and factor XIII).11
Solvent-detergent processing of plasma also removes
the highest multimers of vWF, so this product may also be
particularly suitable for the treatment of TTP.12 Patients
undergoing plasma exchange have shown a higher re-
sponse rate and lower mortality rate than those given only
plasma infusions.13 Antiplatelet agents such as acetylsali-
Table 1. - Evolution of diagnostic criteria for TTP
Clinical signs Percent of patients
Amorosi et al18 Ridolfi et al19 Rock et al13
Microangiopathic hemolytic anemia 96 98 100
Thrombocytopenia 96 96 100
Neurologic symptoms 92 84 63
Renal disease 88 76 59
Fever 98 59 24
Table 2. - Differences between HUS and TTP.
HUS TTP
Peak age incidence 1-4 years 20-25 years
Male:Female ratio 1 : 1 1 : 2
Prodromal illness Usual Variable
Fever Rare Usual
Neurologic abnormalities Variability Usual
related to renal
failure
Renal disease Usual Usual
Renal failure Common Rare
Hypertension Common Rare
Major organs affected Kidneys Kidneys, brain, heart, pancreas, adrenals
Prognosis Relatively good Relatively poor
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cylic acid and dipyridamole have widespread use as plate-
let-inhibitor drugs. Vincristine, in combination with glu-
cocorticoids and plasma, also has been used. Splenectomy
and intravenous immunoglobulin have been reported to
lead to remission in TTP patients who did not respond to
plasma exchange, or those who had relapsed.14-16
Supportive Treatment
The prompt administration of appropriate therapy is
essential.13 It is equally important to recognize that plate-
let transfusions are contraindicated, despite the frequently
encountered severe thrombocytopenia, which may aggra-
vate the disease.11 Red blood cell replacement is frequently
necessary before the abatement of the hemolysis with
plasma exchange therapy. The requirement is proportional
to the degree of hemolysis. The packed red blood cells are
depleted of platelets and can be given safely.
Acute renal failure is the result of severe injury to the
renal vasculature, as a result of the primary endothelial
injury or of a heavy presence of the microthrombotic le-
sions characteristic of TTP. The renal failure may often
be severe and requires frequent hemodialysis. Renal vas-
cular lesions in TTP leads to ischemia results in the acti-
vation of the renin-angiotensin system. In the case of se-
vere involvement of the kidney, this activation is maxi-
mal and prompt control of severe hypertension by angio-
tensin converting enzyme inhibitors is needed to prevent
acute hypertensive complications.
Prognosis
Before the late 1970s, almost all patients with TTP
died of their illness within days or weeks. Since the intro-
duction of corticosteroids, platelet-inhibitor drugs and
splenectomy, the survival rate increased almost 50%. By
means of supportive care and a variable combination of
therapeutic modalities (currently including intensive
plasma exchange), as many as 85-90% of patients with
TTP may eventually recover. However, Sumack et al have
published that more than one third of patients who sur-
vive an acute episode of TTP will have at least one re-
lapse during the following ten years.17
In conclusion, TTP is a rare, but life-threatening dis-
order. Prognosis is good with immediate diagnosis and
adequate treatment with plasma exchange.
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